Al­ler­gan antes up $90M in a land­mark CRISPR/Cas9 col­lab­o­ra­tion with Ed­i­tas on eye dis­eases

Al­ler­gan is jump­ing in­to the CRISPR busi­ness.

The biotech struck a deal to part­ner with CRISPR/Cas9 leader Ed­i­tas $ED­IT on up to five pro­grams aimed at cur­ing eye dis­eases. And the pack­age in­cludes Ed­i­tas’ lead pro­gram for Leber Con­gen­i­tal Amau­ro­sis (LCA10), which is cur­rent­ly wrap­ping pre­clin­i­cal re­search with an eye to mov­ing in­to the clin­ic in pos­si­bly the first hu­man CRISPR study in the US.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER